How Big Pharma rakes in Profits from Deadly Drugs

How the pharmaceutical industry avoids accountability with ‘off label’ drugs

Ben Swann‘s channel, 6 July 2016.

Episode 4 of 4 in Truth in Media series on Big Pharma manipulation of healthcare.

More Information

  • The fourth episode of this serie, How Big Pharma Uses Off-Label Drugs, illustrates how pharmaceutical companies have made massive profits in spite of being ordered to pay enormous settlements related to harmful side effects of certain drugs.
  • How Big Pharma Avoids Accountability With ‘Off Label’ Drugs, Truth In Media, July 8, 2016.
More Videos

Clomiphene citrate and hormonal cocktails: women as test-sites for fertility drugs

Clomiphene citrate has a chemical structure similar to DES


Clomiphene citrate is a drug that has been given to women for conventional fertility treatment for over 20 years. It is also now being administered—often in connection with other hormone-like drugs to an increasing number of women in IVF programmes (many of whom are fertile), in order to stimulate egg cell growth. Clomiphene citrate is handed out as if it were a “safe drug.”

This paper analyses some of the medical and scientific literature on the drug including its effect on the women themselves and the children born after such treatment. It also incorporates our research with women who have used the drug.

Women’s Studies International Forum, Feminism and science: In memory of Ruth Bleier, Volume 12, Issue 3, Pages 333-348, 1989.

Full PDF: School of Humanities, Deakin University, Geelong, 3217, Victoria, Australia,

Cocktails image via bustle.

What surfaces is a disturbing array of health hazards ranging from depression, nausea, and weight gain, to burst ovaries, adhesions, and the promotion of cancer leading to death in some women, worrying rates of birth anomalies in the children and severe chromosomal aberrations in egg cell development. Of great concern is the evidence that the drug may stay in a woman’s body for at least six weeks. Since clomiphene citrate has a chemical structure similar to DES there may be as yet unknown long-term adverse effects similar to those from DES. Given the fact that all these “side-effects” have stirred considerable debate in the medical and scientific literature, we are shocked to learn that

  • (a) the women taking the drug are not informed of its possible detrimental effects;
  • (b) and that researchers continue to state, contrary to scientific evidence, that the drug has no side effects.

We posit that the potential risks from the drug are too great to administer it to any women and demand the development of a different science that places values on women’s lives instead of using them as “living test-sites.”

More DES DiEthylStilbestrol Resources

Diethyl-Stilbestrol prescription tablets 1 mg

DES prescription tablets manufactured by Eli Lilly & Co, Indianapolis, USA

diethyl-stilbestrol image
Diethyl-Stilbestrol prescription tablets manufactured by Eli Lilly & Co, Indianapolis, USA.

DES was sold under many names including Distilbène®, Stilbetin®, Stilboestrol-Borne®, Benzestrol®, Chlorotrianisene®, Estrobene® and Estrosyn® to name just a few.

Many different companies manufactured and marketed this drug under more than 200 different brand names.

These Diethyl-Stilbestrol prescription drugs – 100 tablets of 1 mg – were manufactured by: Eli Lilly & Co, Indianapolis, USA.

“This is a patent drug and serious consequences may result if used other that under constant medical supervision”

the WARNING says… Unfortunately we have seen serious consequences for millions of people

DES Drug Pictures
More DES DiEthylStilbestrol resources

Fausses maladies… vrais médicaments !

Le “disease mongering” expliqué par Prescrire et le professeur Even

Vidéo publiée le 22 mai 2014 par On n’est plus des pigeons!.

Peut-on faire confiance aux pharmacies et à tous les médicaments prescrits?


Many medical professionals not willing to declare the money paid to them by drug companies

Doctors getting biggest payments from drug companies don’t declare them ; the UK General Medical Council says it can’t force them…

Last week the ABPI published the Disclosure UK database listing details of the fees and benefits in kind paid by the pharmaceutical industry to doctors, pharmacists, nurses, and healthcare organisations.

However, only healthcare professionals and organisations consenting to being identified were named, and the remainder of the information was published in aggregate form.

Doctors getting biggest payments from drug companies don’t declare them on new website, The BMJ 354/bmj.i3679, 01 July 2016.
Image via Truthout.

Data shows that only 70% of medical professionals in receipt of payments from companies agreed to have the data disclosed. However the 30% who did not agree to disclosure received 52% of the payments registered.

GMC says it can’t force doctors to disclose payments from drug companies, The BMJ 354/bmj.i3806, 07 July 2016.

The UK General Medical Council has admitted that it does not have the legal power to force doctors to disclose details of payments and benefits they receive from the pharmaceutical industry.

Acetaminophen use in pregnancy and risk of autism spectrum disorders in childhood

Popular painkiller like Tylenol linked to autism in boys

Acetaminophen during pregnancy linked to autism, environmentalhealthnews, July 6, 2016.
Image viaDaniel Lobo.

Boys exposed before birth to a popular pain reliever in many brands including Tylenol were more likely to have symptoms of autism during childhood, according to a new study of mothers and children in Spain.


Acetaminophen is extensively used during pregnancy. But there is a lack of population-representative cohort studies evaluating its effects on a range of neuropsychological and behavioural endpoints. We aimed to assess whether prenatal exposure to acetaminophen is adversely associated with neurodevelopmental outcomes at 1 and 5 years of age.

Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms, NCBI PubMed PMID: 27353198, 2016 Jun 28.

This Spanish birth cohort study included 2644 mother-child pairs recruited during pregnancy. The proportion of liveborn participants evaluated at 1 and 5 years was 88.8% and 79.9%, respectively. Use of acetaminophen was evaluated prospectively in two structured interviews. Ever/never use and frequency of use (never, sporadic, persistent) were measured. Main neurodevelopment outcomes were assessed using Childhood Autism Spectrum Test (CAST), Conner’s Kiddie Continuous Performance Test (K-CPT) and ADHD-DSM-IV form list. Regression models were adjusted for social determinants and co-morbidities.

Over 40% of mothers reported using acetaminophen. Ever-exposed offspring had higher risks of presenting more hyperactivity/impulsivity symptoms [incidence rate ratio (IRR) = 1.41, 95% confidence interval (CI) 1.01-1.98), K-CPT commission errors (IRR = 1.10, 1.03-1.17), and lower detectability scores (coefficient β = -0.75, -0.13–0.02). CAST scores were increased in ever-exposed males (β = 0.63, 0.09-1.18). Increased effect sizes of risks by frequency of use were observed for hyperactivity/impulsivity symptoms (IRR = 2.01, 0.95-4.24) in all children, K-CPT commission errors (IRR = 1.32, 1.05-1.66) and detectability (β = -0.18, -0.36-0.00) in females, and CAST scores in males (β = 1.91, 0.44-3.38).

Prenatal acetaminophen exposure was associated with a greater number of autism spectrum symptoms in males and showed adverse effects on attention-related outcomes for both genders. These associations seem to be dependent on the frequency of exposure.

Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: A Danish national birth cohort study, NCBI PubMed PMID: 26688372, 2015 Dec 21.

And a much-publicized study last year found that women who reported using acetaminophen during pregnancy were about 50 percent more likely to have a child with autism and other behavioral issues such as hyperactivity and impulsivity.


Acetaminophen (paracetamol) is the most commonly used pain and fever medication during pregnancy. Previously, a positive ecological correlation between acetaminophen use and autism spectrum disorders (ASD) has been reported but evidence from larger studies based on prospective data is lacking.

We followed 64,322 children and mothers enrolled in the Danish National Birth Cohort (DNBC; 1996-2002) for average 12.7 years to investigate whether acetaminophen use in pregnancy is associated with increased risk of ASD in the offspring. Information on acetaminophen use was collected prospectively from three computer-assisted telephone interviews. We used records from the Danish hospital and psychiatric registries to identify diagnoses of ASD. At the end of follow up, 1,027 (1.6%) children were diagnosed with ASD, 345 (0.5%) with infantile autism.

We found that 31% of ASD (26% of infantile autism) have also been diagnosed with hyperkinetic disorders. More than 50% women reported ever using acetaminophen in pregnancy. We used Cox proportional hazards model to estimate hazard ratio (HR) and 95% confident interval (CI). Prenatal use of acetaminophen was associated with an increased risk of ASD accompanied by hyperkinetic symptoms (HR = 1.51 95% CI 1.19-1.92), but not with other ASD cases (HR = 1.06 95% CI 0.92-1.24). Longer duration of use (i.e., use for >20 weeks in gestation) increased the risk of ASD or infantile autism with hyperkinetic symptoms almost twofold.

Maternal use of acetaminophen in pregnancy was associated with ASD with hyperkinetic symptoms only, suggesting acetaminophen exposure early in fetal life may specifically impact this hyperactive behavioral phenotype.

Can prenatal alcohol exposure cause a distinct DNA methylation pattern?

DNA methylation signature of human fetal alcohol spectrum disorder


Prenatal alcohol exposure is the leading preventable cause of behavioral and cognitive deficits, which may affect between 2 and 5 % of children in North America. While the underlying mechanisms of alcohol’s effects on development remain relatively unknown, emerging evidence implicates epigenetic mechanisms in mediating the range of symptoms observed in children with fetal alcohol spectrum disorder (FASD). Thus, we investigated the effects of prenatal alcohol exposure on genome-wide DNA methylation in the NeuroDevNet FASD cohort, the largest cohort of human FASD samples to date.

DNA methylation signature of human fetal alcohol spectrum disorder, BioMed Central, epigeneticsandchromatin, 17 June 2016.

Genome-wide DNA methylation patterns of buccal epithelial cells (BECs) were analyzed using the Illumina HumanMethylation450 array in a Canadian cohort of 206 children (110 FASD and 96 controls). Genotyping was performed in parallel using the Infinium HumanOmni2.5-Quad v1.0 BeadChip.

After correcting for the effects of genetic background, we found 658 significantly differentially methylated sites between FASD cases and controls, with 41 displaying differences in percent methylation change >5 %. Furthermore, 101 differentially methylated regions containing two or more CpGs were also identified, overlapping with 95 different genes. The majority of differentially methylated genes were highly expressed at the level of mRNA in brain samples from the Allen Brain Atlas, and independent DNA methylation data from cortical brain samples showed high correlations with BEC DNA methylation patterns. Finally, overrepresentation analysis of genes with up-methylated CpGs revealed a significant enrichment for neurodevelopmental processes and diseases, such as anxiety, epilepsy, and autism spectrum disorders.

These findings suggested that prenatal alcohol exposure is associated with distinct DNA methylation patterns in children and adolescents, raising the possibility of an epigenetic biomarker of FASD.

You want to drill where ?!

What the frack are we doing to our planet?

Sources and More Information

Pregnant? How to protect your child from harmful chemicals

Unborn children and kids should be protected from EDCs


Trois Femmes et un Lobby des Pesticides

Nos vies empoisonnées, nos enfants en danger, quel principe de précaution?

Ça nous concerne, Facebook 1719378691655626, 05 July 2016.

Consommation / Société / Vie Pratique… ça nous concerne! Retrouvez Valérie Expert sur LCI du lundi au vendredi de 9h40 à 11h.

Les perturbateurs endocriniens, substances chimiques, sont présentes dans de nombreux objets de consommation courante : plastiques, résidus de pesticides sur les fruits et légumes, OGM, cosmétiques, lunettes, semelles de chaussures… Ils interagissent avec le système hormonal et seraient responsables de l’augmentation de certains cancers, selon des associations impliquées dans les problèmes de santé liés à l’environnement. L’Union européenne est accusée d’avoir repoussé la réglementation les concernant sous la pression des lobbies.

Sur le même sujet

Le Distilbène, Perturbateur Endocrinien